Sonova quarterly update and guidance, shares tracked against hearing-aid peers
25.06.2026 - 20:14:36 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 20:14.
Sonova Holding AG (CH0012549785) remains a key European hearing-care name on SIX Swiss Exchange, with investors digesting its most recent quarterly figures and guidance. The group reported organic sales growth in the mid-single-digit range and reiterated its full-year outlook, according to its latest investor presentation and earnings material.
Latest numbers and guidance detail
In its most recent reported quarter for financial year 2024/25, Sonova highlighted revenue growth driven by the Audiological Care segment and higher unit volumes in hearing instruments, while reporting continued cost pressures in logistics and components, as disclosed in the company's earnings documentation. The company maintained its full-year organic sales growth target in the mid-single-digit percentage range and an adjusted EBITA margin broadly in line with the prior year, according to the same material. The Sonova investor-relations page provides the detailed quarterly presentation and guidance commentary
Management again pointed to structural demand from aging populations and higher penetration of hearing solutions in developed markets, while also noting that comparisons with the strong prior-year base in the premium product tier remain challenging. The group continued its share buyback program announced previously, using excess cash generation to repurchase a defined volume of shares within its capital framework, according to company disclosures.
Analyst views, valuation and peer comparison
Sell-side analysts following Sonova broadly expect continued top-line growth in the mid-single-digit range and a gradual expansion of margins as integration synergies and efficiency measures take hold, based on recent consensus data compiled by market platforms. Several European brokers maintain positive or neutral ratings, with target prices that imply moderate upside from recent trading levels, reflecting a quality premium versus parts of the medtech sector. Reuters market coverage regularly summarizes Sonova estimates, valuation multiples and rating distribution
Investors frequently benchmark Sonova against listed hearing-aid peers Demant and GN Store Nord, looking at relative valuation metrics such as forward price-to-earnings and enterprise-value-to-EBIT. While the Danish peers have at times traded at a discount following competitive and execution issues, Sonova traditionally commands a solid valuation supported by its strong distribution network and brand positioning. The stock also forms part of Switzerland's broader medtech and health-care complex, alongside companies such as Straumann and Alcon, which attract international institutional investors.
All news and analysis on the Sonova shares
Further coverage of Sonova Holding AG, from earnings reports to strategy updates and brokerage research, can be found on our dedicated topic page and in the company's investor-relations material.
What Sonova sells in hearing care
Sonova generates most of its revenue from hearing aids and related audiological solutions under brands such as Phonak, Unitron and Hansaton, offering devices across premium, mid-range and essential segments. The group also sells cochlear implants and wireless communication solutions that extend speech understanding in demanding acoustic environments.
Where the stock trades today
Sonova shares trade on SIX Swiss Exchange under the ticker SONV at around a triple-digit Swiss franc level, with the company forming part of Switzerland's health-care and medtech universe that international investors follow closely; the latest available data show a multi-billion-franc market capitalization.
Sonova at a glance
- Company: Sonova Holding AG
- ISIN: CH0012549785
- WKN: 125497
- Ticker: SONV
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-25, 18:00): [latest verified] CHF
- Market cap: [latest verified] CHF (as of 2026-06-25)
- Sector / industry: Health Care / Medical Devices
- Index membership: SPI and other Swiss equity indices
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
